Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.
Identifieur interne : 002784 ( PubMed/Curation ); précédent : 002783; suivant : 002785Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.
Auteurs : Chuan-Hai Zhang [République populaire de Chine] ; Jia-Hai Lu ; Yi-Fei Wang ; Huan-Ying Zheng ; Sheng Xiong ; Mei-Ying Zhang ; Xin-Jian Liu ; Jiu-Xiang Li ; Zhuo-Yue Wan ; Xin-Ge Yan ; Shu-Yuan Qi ; Zhiyong Cui ; Biliang ZhangSource :
- Vaccine [ 0264-410X ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (analyse), Anticorps antiviraux (biosynthèse), Données de séquences moléculaires, Immunisation, Immunoglobuline G (analyse), Immunoglobuline G (biosynthèse), Immunoglobuline M (analyse), Immunoglobuline M (biosynthèse), Souris, Souris de lignée BALB C, Spécificité des anticorps, Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Technique de Western, Test ELISA, Tests de neutralisation, Vaccins antiviraux (immunologie), Vaccins inactivés, Virus du SRAS (immunologie).
- MESH :
- analyse : Anticorps antiviraux, Immunoglobuline G, Immunoglobuline M.
- biosynthèse : Anticorps antiviraux, Immunoglobuline G, Immunoglobuline M.
- immunologie : Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Données de séquences moléculaires, Immunisation, Souris, Souris de lignée BALB C, Spécificité des anticorps, Technique de Western, Test ELISA, Tests de neutralisation, Vaccins inactivés.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (analysis), Antibodies, Viral (biosynthesis), Antibody Specificity, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Immunization, Immunoglobulin G (analysis), Immunoglobulin G (biosynthesis), Immunoglobulin M (analysis), Immunoglobulin M (biosynthesis), Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Vaccines, Inactivated, Viral Vaccines (immunology).
- MESH :
- chemical , analysis : Antibodies, Viral, Immunoglobulin G, Immunoglobulin M.
- chemical , biosynthesis : Antibodies, Viral, Immunoglobulin G, Immunoglobulin M.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Viral Vaccines.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Antibody Specificity, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Immunization, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Vaccines, Inactivated.
Abstract
The immunogenicity of a candidate-inactivated vaccine prepared from SARS-CoV F69 strain was evaluated in Balb/c mice. Potent humoral immune responses were induced under the elicitation of three times of immunizations at 2-week intervals with this vaccine, combined with three types of adjuvants (Freund's adjuvant, Al(OH)(3) adjuvant and CpG adjuvant). Titers of specific IgG antibodies in three test groups all peaked in the sixth week after first vaccination, but significant differences existed in the kinetics of specific IgG antibody levels. The strong neutralizing capacity exhibited in micro-cytopathic effect neutralization tests indicated the specific antibodies are protective. Western blot assay further demonstrated the specificity of the induced serum antibodies.
DOI: 10.1016/j.vaccine.2004.11.073
PubMed: 15837220
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002784
Links to Exploration step
pubmed:15837220Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.</title><author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Biomedicine Research and Development Center, Jinan University, Guangzhou 510632, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Biomedicine Research and Development Center, Jinan University, Guangzhou 510632</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name></author><author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name></author><author><name sortKey="Zheng, Huan Ying" sort="Zheng, Huan Ying" uniqKey="Zheng H" first="Huan-Ying" last="Zheng">Huan-Ying Zheng</name></author><author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name></author><author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name></author><author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name></author><author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name></author><author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name></author><author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name></author><author><name sortKey="Qi, Shu Yuan" sort="Qi, Shu Yuan" uniqKey="Qi S" first="Shu-Yuan" last="Qi">Shu-Yuan Qi</name></author><author><name sortKey="Cui, Zhiyong" sort="Cui, Zhiyong" uniqKey="Cui Z" first="Zhiyong" last="Cui">Zhiyong Cui</name></author><author><name sortKey="Zhang, Biliang" sort="Zhang, Biliang" uniqKey="Zhang B" first="Biliang" last="Zhang">Biliang Zhang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15837220</idno><idno type="pmid">15837220</idno><idno type="doi">10.1016/j.vaccine.2004.11.073</idno><idno type="wicri:Area/PubMed/Corpus">002784</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002784</idno><idno type="wicri:Area/PubMed/Curation">002784</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002784</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.</title><author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Biomedicine Research and Development Center, Jinan University, Guangzhou 510632, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Biomedicine Research and Development Center, Jinan University, Guangzhou 510632</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name></author><author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name></author><author><name sortKey="Zheng, Huan Ying" sort="Zheng, Huan Ying" uniqKey="Zheng H" first="Huan-Ying" last="Zheng">Huan-Ying Zheng</name></author><author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name></author><author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name></author><author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name></author><author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name></author><author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name></author><author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name></author><author><name sortKey="Qi, Shu Yuan" sort="Qi, Shu Yuan" uniqKey="Qi S" first="Shu-Yuan" last="Qi">Shu-Yuan Qi</name></author><author><name sortKey="Cui, Zhiyong" sort="Cui, Zhiyong" uniqKey="Cui Z" first="Zhiyong" last="Cui">Zhiyong Cui</name></author><author><name sortKey="Zhang, Biliang" sort="Zhang, Biliang" uniqKey="Zhang B" first="Biliang" last="Zhang">Biliang Zhang</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (analysis)</term><term>Antibodies, Viral (biosynthesis)</term><term>Antibody Specificity</term><term>Blotting, Western</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Immunization</term><term>Immunoglobulin G (analysis)</term><term>Immunoglobulin G (biosynthesis)</term><term>Immunoglobulin M (analysis)</term><term>Immunoglobulin M (biosynthesis)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Sequence Data</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vaccines, Inactivated</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (analyse)</term><term>Anticorps antiviraux (biosynthèse)</term><term>Données de séquences moléculaires</term><term>Immunisation</term><term>Immunoglobuline G (analyse)</term><term>Immunoglobuline G (biosynthèse)</term><term>Immunoglobuline M (analyse)</term><term>Immunoglobuline M (biosynthèse)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Technique de Western</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term><term>Immunoglobuline M</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term><term>Immunoglobuline M</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Specificity</term><term>Blotting, Western</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Sequence Data</term><term>Neutralization Tests</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Données de séquences moléculaires</term><term>Immunisation</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Technique de Western</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Vaccins inactivés</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The immunogenicity of a candidate-inactivated vaccine prepared from SARS-CoV F69 strain was evaluated in Balb/c mice. Potent humoral immune responses were induced under the elicitation of three times of immunizations at 2-week intervals with this vaccine, combined with three types of adjuvants (Freund's adjuvant, Al(OH)(3) adjuvant and CpG adjuvant). Titers of specific IgG antibodies in three test groups all peaked in the sixth week after first vaccination, but significant differences existed in the kinetics of specific IgG antibody levels. The strong neutralizing capacity exhibited in micro-cytopathic effect neutralization tests indicated the specific antibodies are protective. Western blot assay further demonstrated the specificity of the induced serum antibodies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15837220</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>24</Issue><PubDate><Year>2005</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.</ArticleTitle><Pagination><MedlinePgn>3196-201</MedlinePgn></Pagination><Abstract><AbstractText>The immunogenicity of a candidate-inactivated vaccine prepared from SARS-CoV F69 strain was evaluated in Balb/c mice. Potent humoral immune responses were induced under the elicitation of three times of immunizations at 2-week intervals with this vaccine, combined with three types of adjuvants (Freund's adjuvant, Al(OH)(3) adjuvant and CpG adjuvant). Titers of specific IgG antibodies in three test groups all peaked in the sixth week after first vaccination, but significant differences existed in the kinetics of specific IgG antibody levels. The strong neutralizing capacity exhibited in micro-cytopathic effect neutralization tests indicated the specific antibodies are protective. Western blot assay further demonstrated the specificity of the induced serum antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuan-hai</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Biomedicine Research and Development Center, Jinan University, Guangzhou 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jia-hai</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yi-fei</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Huan-ying</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Sheng</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mei-ying</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xin-jian</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiu-xiang</ForeName><Initials>JX</Initials></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Zhuo-yue</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xin-ge</ForeName><Initials>XG</Initials></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Shu-Yuan</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Zhiyong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Biliang</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AY313906</AccessionNumber><AccessionNumber>AY394989</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15837220</ArticleId><ArticleId IdType="pii">S0264-410X(05)00093-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2004.11.073</ArticleId><ArticleId IdType="pmc">PMC7115646</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2003 Jan 17;21(5-6):368-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12531634</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2001 Jan 8;19(11-12):1538-46</Citation><ArticleIdList><ArticleId IdType="pubmed">11163680</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2003 Feb;69(2):163-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12683403</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 2000;247:1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10689776</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2002 May 31;20 Suppl 3:S24-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12184361</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chin Sci Bull. 2003;48(23):2621-2625</Citation><ArticleIdList><ArticleId IdType="pubmed">32214708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2003 Mar 28;52(12):241-6, 248</Citation><ArticleIdList><ArticleId IdType="pubmed">12680518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(13):7217-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15194798</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002784 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002784 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15837220
|texte= Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15837220" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |